Leerink Partnrs Weighs in on 908 Devices Inc.’s Q1 2025 Earnings (NASDAQ:MASS)

908 Devices Inc. (NASDAQ:MASS) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for 908 Devices in a research note issued to investors on Tuesday, April 30th. Leerink Partnrs analyst P. Souda forecasts that the company will earn ($0.31) per share for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.16) EPS.

908 Devices Stock Performance

Shares of NASDAQ:MASS opened at $5.68 on Thursday. The company has a 50 day moving average price of $6.59 and a two-hundred day moving average price of $7.08. 908 Devices has a 52 week low of $4.85 and a 52 week high of $12.51. The company has a market capitalization of $187.33 million, a PE ratio of -5.31 and a beta of 1.02.

908 Devices (NASDAQ:MASS) last issued its earnings results on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.03. 908 Devices had a negative net margin of 68.57% and a negative return on equity of 20.47%. The firm had revenue of $9.99 million during the quarter, compared to the consensus estimate of $9.29 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis.

Institutional Investors Weigh In On 908 Devices

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in shares of 908 Devices during the fourth quarter worth $133,000. Values First Advisors Inc. increased its position in shares of 908 Devices by 24.5% during the third quarter. Values First Advisors Inc. now owns 16,726 shares of the company’s stock worth $111,000 after acquiring an additional 3,294 shares in the last quarter. Arete Wealth Advisors LLC increased its position in shares of 908 Devices by 35.8% during the third quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company’s stock worth $152,000 after acquiring an additional 5,997 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of 908 Devices by 15.3% during the third quarter. New York State Common Retirement Fund now owns 70,525 shares of the company’s stock worth $470,000 after acquiring an additional 9,346 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of 908 Devices by 11.1% during the third quarter. Bank of New York Mellon Corp now owns 93,775 shares of the company’s stock worth $625,000 after acquiring an additional 9,393 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.